ANDA 202846, held by Invagen Pharms. Phentermine Hydrochloride.
As of Nov 16, 2026, ANDA 202846 (Phentermine Hydrochloride), held by Invagen Pharms, was first approved by FDA on Feb 5, 2014, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 5, 2014 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Phentermine Hydrochloride37.5MG · capsule;oral | Phentermine Hydrochloride | Discontinued |
| May 31, 2017 | Supplement 2Labeling · Standard review | Approved | None posted |
| Feb 5, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters